FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945401327> ?p ?o ?g. }

• W2945401327 abstract "Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections.1 The risk of developing these infections increases when white blood cell (WBC) counts, particularly the absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia1 (ANC < 500/μL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, currently in approximately one in six of all chemotherapy patients,2 and it is associated with a high rate of mortality,3 where 11% of patients die after one or several hospitalizations.4, 5 In the United States alone, the associated cost due to such hospitalizations accounts for $2.7B dollars annually,2 contributing to up to 40% of the total cost of cancer treatments.6 Early detection of severe neutropenia can be key to preventing FN. Timely detection could enable preventive therapies, such as granulocyte-colony stimulating factors7 or prophylactic antibiotics, to be administered. Unfortunately, current neutrophil monitoring options are inadequate to monitor severe neutropenia with sufficient frequency to allow for early detection and therapy optimization. Their reliance on the extraction and analysis of blood samples, which requires trained medical oversight, typically limits this testing to clinical settings. Cost-effective high frequency monitoring of this parameter, therefore, requires a new method that can be used by outpatients with minimal risk. To address this unmet need, we propose the first noninvasive technology that can automatically screen patients for severe neutropenia without requiring blood draws, thus enabling patients to have more frequent access to this test. Our proposed noninvasive device is a compact microscopy system that can acquire high-resolution, high-frame-rate videos of superficial capillaries (Figure S1),8 coupled with an automated software pipeline that can analyze those videos for a measurement of neutropenia. This design potentially opens the door to the use of such instrumentation in the patient's home. We conducted a clinical study at two independent hospitals to assess the ability of our device and algorithm to detect severe neutropenia in chemotherapy patients undergoing standard therapy. In previously reported work,8 we demonstrated an initial proof-of-concept of this principle using a small set of nailfold capillary video samples,8 which were manually analyzed through visual inspection by human experts. Here, we further demonstrated and validated a fully automated software analysis pipeline and extended our results to a larger cohort of 44 patients. The individuals enrolled in our study were selected from patients undergoing high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) at the Massachusetts General Hospital (MGH) Boston, Massachusetts, United States, or at Hospital Universitario La Paz (HULP), Madrid, Spain. This specific patient population was selected due to its clinical relevance and highly standardized regimen which allows for predictable evolution of neutrophil count dynamics, ensuring a transition from baseline values (ANC > 500/μL) to severe neutropenia (ANC < 500/μL), as well as an opportunity to acquire multiple video samples at different time points (Figure S2). The protocol was approved by the corresponding IRB boards for a total of 44 patients to be included in this study (Supplementary Methods). From the 44 enrolled subjects, video sessions containing at least one suitable capillary in their field of view were collected (Supplementary Methods) at different stages of the ASCT treatment (Figure S2). Specifically, a technical operator ensured that at least one capillary fulfilled the required quality criteria for analysis.8 This resulted in a total of 115 imaging sessions from 42 subjects, with an average of three sessions per subject. Each imaging session is associated with a reference blood test performed by the gold-standard clinical-laboratory analyzer whose values, including the reference ANCs, are provided in the Supplementary Methods (Figure S3). To confirm the findings of our previous work correlating the number of capillaries analyzed with the classification accuracy,8 we evaluated the diagnostic performance of our automatic pipeline on three distinct sets of imaging sessions: those that had at least one suitable capillary (all 115 imaging sessions from all 42 patients), at least two (100 sessions from 38 patients), or at least three (89 sessions from 35 patients). Following the acquisition of these sessions using our clinical prototype,8 an automated software pipeline composed of several processing steps (Supplementary Methods) was designed to analyze the raw videos. The analysis of each video session produced a separate data point consisting in a unitless “Leuko Index,” which was used to classify severe-neutropenic cases (ANC < 500/μL) from the rest (ANC > 500/μL). To produce this index, our pipeline first detected nailfold capillaries in the corresponding video session, then counted passing optical-absorption gaps—which as discussed in Bourquard et al8 can be considered as proxies of flowing neutrophils—inside these capillaries, and finally averaged the individual capillary counts into one single value. Results were then compared against the gold-standard ANC values to determine performance in separating severely neutropenic patients (ANC < 500/μL) from the rest (ANC > 500/μL), giving the opportunity to calculate the rate of correctly classified severe neutropenia cases (true positives) against the rate of false alarms (false positives). The classification performance for all imaging sessions, with at least three suitable capillaries detected, yielded an area under the curve (AUC)9 of 0.95 (Figure 1). The use of all imaging sessions with at least one suitable capillary yielded an AUC of 0.91 (Figure S4), whereas those containing at least two suitable capillaries yielded an AUC of 0.94 (Figure S5). The intrameasurement agreement of our method when using only one, two, or three capillaries per imaging session was shown to increase as more capillaries were used (87% agreement when using 1 vs 2 capillaries and 91.4% agreement when using 2 vs 3 capillaries), see Figure S6. Also, the classification performance improved with the amount of analyzed capillaries per session, with the percentage agreement increasing from 69.8% to 90.9% (Figure S6), which also corroborates previous results.8 These results demonstrate, for the first time, that our noninvasive optical system (Figure S1), coupled with the proposed automated video analysis pipeline (Figure S7), is able to detect severe neutropenia with high accuracy in a patient cohort showing various degrees of ANC values (Figure S3), without the need for a blood draw. Future work includes the refinement of the device hardware to increase the number of suitable capillaries detected in a single session. The current analysis methods may also be adapted in the future to perform quantitative ANC measurements or differential detections of WBC subtypes. Overall, this work demonstrates that patients can be screened for severe neutropenia automatically and noninvasively without the need to draw blood. Our noninvasive blood analysis method opens the door to frequent, precise and personalized management of patients at risk for FN. The authors thank the Madrid-MIT M+Visión Consortium, the Catalyst program, and MIT linQ for their support and guidance in developing this project. They thank Martha L. Gray, Benjamin J. Vakoc, Timothy P. Padera, and all other MIT linQ faculty members who provided invaluable feedback and advice through regular working-group sessions and meetings. This work was supported by the NIH NCI SBIR Program (award no. 1R43CA228920-01A1); the Comunidad de Madrid through the Madrid-MIT M+Visión Consortium; the Center For Future Technologies in Cancer Care through Grant NIH U54 (award no. 4U54EB015403-05); the Wallace H. Coulter Foundation at BU; the Deshpande Center for Technological Innovation; the MIT Sandbox Innovation Fund; and the M+Visión EU FP7-PEOPLE-2011-COFUND Program of the Fundación Madri+d (Comunidad de Madrid). C.C.G., I.B., A.B., and A.S.F. have an issued patent on the proposed technology under patent number US 9,984,277 B2 and title “Systems, Apparatus, and Methods for Analyzing Blood Cell Dynamics”. A.P.T., I.B., A.S.F., A.B., and C.C.G. report honoraria, financial support from, and current employment by Leuko Labs Inc. to conduct this research. I.B., A.S.F., C.C.G., and A.B. hold equity in Leuko Labs Inc. All other authors have nothing to declare. A.P.T. collected and analyzed data, implemented critical elements of the software pipeline, and wrote substantial sections of the manuscript; I.B. analyzed data, provided substantial support in data interpretation, and provided substantial support in software development and quality control; M.J.L.C. supervised the development of the proposed pipeline and contributed in the analysis and interpretation of results; T.V. analyzed data, conceived the software-pipeline structure, and implemented critical elements of the software pipeline; A.S.F. collected data, analyzed results, and provided substantial support on data interpretation; L.S., N.J.D., and A.M.B. provided technical advice and contributed in the manuscript revision; C.C., K.H., M.F.U., C.D.R., and B.V. made substantial contributions to patient recruitment and data acquisition; Y.B.C. and E.P.H. made substantial contributions to the conception and design of our clinical study; C.C.G. and A.B. made substantial contributions to the conception of the initial technological concept, the design of the clinical study, experimental framework, data acquisition, the analysis and interpretation of data, and supervised the manuscript writing and the overall development of the proposed method; All authors revised the article critically for important intellectual content and approved of its submission. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W2945401327 created "2019-05-29" @default.
• W2945401327 creator A5008900668 @default.
• W2945401327 creator A5011324183 @default.
• W2945401327 creator A5012910949 @default.
• W2945401327 creator A5021715576 @default.
• W2945401327 creator A5022934126 @default.
• W2945401327 creator A5035186913 @default.
• W2945401327 creator A5037401826 @default.
• W2945401327 creator A5042958049 @default.
• W2945401327 creator A5052133740 @default.
• W2945401327 creator A5063090137 @default.
• W2945401327 creator A5070150597 @default.
• W2945401327 creator A5071416130 @default.
• W2945401327 creator A5078299466 @default.
• W2945401327 creator A5078433579 @default.
• W2945401327 creator A5083127912 @default.
• W2945401327 creator A5084484243 @default.
• W2945401327 creator A5090060613 @default.
• W2945401327 date "2019-06-06" @default.
• W2945401327 modified "2023-10-16" @default.
• W2945401327 title "Automated detection of neutropenia using noninvasive video microscopy of superficial capillaries" @default.
• W2945401327 cites W1804059878 @default.
• W2945401327 cites W2029426756 @default.
• W2945401327 cites W2083336892 @default.
• W2945401327 cites W2341557816 @default.
• W2945401327 cites W2412251261 @default.
• W2945401327 cites W2564450612 @default.
• W2945401327 cites W2610097533 @default.
• W2945401327 cites W2795027534 @default.
• W2945401327 doi "https://doi.org/10.1002/ajh.25516" @default.
• W2945401327 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6684956" @default.
• W2945401327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31120579" @default.
• W2945401327 hasPublicationYear "2019" @default.
• W2945401327 type Work @default.
• W2945401327 sameAs 2945401327 @default.
• W2945401327 citedByCount "9" @default.
• W2945401327 countsByYear W29454013272020 @default.
• W2945401327 countsByYear W29454013272021 @default.
• W2945401327 countsByYear W29454013272022 @default.
• W2945401327 countsByYear W29454013272023 @default.
• W2945401327 crossrefType "journal-article" @default.
• W2945401327 hasAuthorship W2945401327A5008900668 @default.
• W2945401327 hasAuthorship W2945401327A5011324183 @default.
• W2945401327 hasAuthorship W2945401327A5012910949 @default.
• W2945401327 hasAuthorship W2945401327A5021715576 @default.
• W2945401327 hasAuthorship W2945401327A5022934126 @default.
• W2945401327 hasAuthorship W2945401327A5035186913 @default.
• W2945401327 hasAuthorship W2945401327A5037401826 @default.
• W2945401327 hasAuthorship W2945401327A5042958049 @default.
• W2945401327 hasAuthorship W2945401327A5052133740 @default.
• W2945401327 hasAuthorship W2945401327A5063090137 @default.
• W2945401327 hasAuthorship W2945401327A5070150597 @default.
• W2945401327 hasAuthorship W2945401327A5071416130 @default.
• W2945401327 hasAuthorship W2945401327A5078299466 @default.
• W2945401327 hasAuthorship W2945401327A5078433579 @default.
• W2945401327 hasAuthorship W2945401327A5083127912 @default.
• W2945401327 hasAuthorship W2945401327A5084484243 @default.
• W2945401327 hasAuthorship W2945401327A5090060613 @default.
• W2945401327 hasBestOaLocation W29454013271 @default.
• W2945401327 hasConcept C142724271 @default.
• W2945401327 hasConcept C147080431 @default.
• W2945401327 hasConcept C2993775838 @default.
• W2945401327 hasConcept C71924100 @default.
• W2945401327 hasConcept C86803240 @default.
• W2945401327 hasConcept C95444343 @default.
• W2945401327 hasConceptScore W2945401327C142724271 @default.
• W2945401327 hasConceptScore W2945401327C147080431 @default.
• W2945401327 hasConceptScore W2945401327C2993775838 @default.
• W2945401327 hasConceptScore W2945401327C71924100 @default.
• W2945401327 hasConceptScore W2945401327C86803240 @default.
• W2945401327 hasConceptScore W2945401327C95444343 @default.
• W2945401327 hasFunder F4320306300 @default.
• W2945401327 hasFunder F4320313831 @default.
• W2945401327 hasFunder F4320332423 @default.
• W2945401327 hasIssue "8" @default.
• W2945401327 hasLocation W29454013271 @default.
• W2945401327 hasLocation W29454013272 @default.
• W2945401327 hasLocation W29454013273 @default.
• W2945401327 hasLocation W29454013274 @default.
• W2945401327 hasLocation W29454013275 @default.
• W2945401327 hasLocation W29454013276 @default.
• W2945401327 hasLocation W29454013277 @default.
• W2945401327 hasOpenAccess W2945401327 @default.
• W2945401327 hasPrimaryLocation W29454013271 @default.
• W2945401327 hasRelatedWork W1968615574 @default.
• W2945401327 hasRelatedWork W1980010528 @default.
• W2945401327 hasRelatedWork W2003899099 @default.
• W2945401327 hasRelatedWork W2008007327 @default.
• W2945401327 hasRelatedWork W2080347877 @default.
• W2945401327 hasRelatedWork W2148568614 @default.
• W2945401327 hasRelatedWork W2353131506 @default.
• W2945401327 hasRelatedWork W2401739423 @default.
• W2945401327 hasRelatedWork W417320600 @default.
• W2945401327 hasRelatedWork W590226782 @default.
• W2945401327 hasVolume "94" @default.
• W2945401327 isParatext "false" @default.
• W2945401327 isRetracted "false" @default.
• W2945401327 magId "2945401327" @default.
• W2945401327 workType "article" @default.